Filtered By:
Condition: Sickle Cell Anemia

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 1318 results found since Jan 2013.

Coexistent Sickle Cell Disease Has No Impact on the Safety or Outcome of Lytic Therapy in Acute Ischemic Stroke Clinical Sciences
Conclusions—Coexistent SCD had no significant impact on the safety or outcome of thrombolytic therapy in acute ischemic stroke. Although the sample size is relatively small, these data suggest that adults with SCD and acute ischemic stroke should be treated with thrombolysis, if they otherwise qualify. Addition studies, however, should track the intracranial hemorrhage rate and provide information on other SCD-related care such as transfusion.
Source: Stroke - February 26, 2017 Category: Neurology Authors: Robert J. Adams, Margueritte Cox, Shelly D. Ozark, Julie Kanter, Phillip J. Schulte, Ying Xian, Gregg C. Fonarow, Eric E. Smith, Lee H. Schwamm Tags: Ischemic Stroke, Transient Ischemic Attack (TIA) Original Contributions Source Type: research

Sickle Cell Trait and Incident Ischemic Stroke in the Atherosclerosis Risk in Communities Study Clinical Sciences
Conclusions— We observed an increased risk of ischemic stroke in blacks with SCT. Further investigation of the incidence and pathophysiology of stroke in patients with SCT is warranted.
Source: Stroke - September 22, 2014 Category: Neurology Authors: Caughey, M. C., Loehr, L. R., Key, N. S., Derebail, V. K., Gottesman, R. F., Kshirsagar, A. V., Grove, M. L., Heiss, G. Tags: Genetics of Stroke, Risk Factors for Stroke, Epidemiology Clinical Sciences Source Type: research

Oral Contraceptive Use and Incident Stroke in Women with Sickle Cell Disease (S55.007)
Conclusions:The four fold higher risk of incident stroke associated with use of oral contraceptives in women with sickle cell disease can be mitigated by avoiding cigarette smoking.Disclosure: Dr. Zafar has nothing to disclose. Dr. Malik has nothing to disclose. Dr. Umair has nothing to disclose. Dr. Nickles has nothing to disclose. Dr. Zarar has nothing to disclose. Dr. Suri has nothing to disclose. Dr. Qureshi has nothing to disclose.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Zafar, T., Adil, M., Umair, M., Chaudhry, S., Zarar, A., Suri, M., Qureshi, A. Tags: Pediatric Stroke and Stroke in the Young Source Type: research

Moyamoya Disease in Children: Results of the International Pediatric Stroke Study (S55.001)
Conclusions: The definition of MMD is variable, and may influence reported outcomes. The presence of additional stroke risk factors in over half of patients implies a multifactorial etiology. Our data suggest that vascular occlusion contributes to recurrence, and may be an important predictor in this population.Disclosure: Dr. Lee has nothing to disclose. Dr. Rivkin has nothing to disclose. Dr. Kirton has nothing to disclose. Dr. DeVeber has nothing to disclose. Dr. Elbers has nothing to disclose.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Lee, S., Rivkin, M., Kirton, A., DeVeber, G., Elbers, J. Tags: Pediatric Stroke and Stroke in the Young Source Type: research

Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association AHA/ASA Guideline
The aim of this updated guideline is to provide comprehensive and timely evidence-based recommendations on the prevention of future stroke among survivors of ischemic stroke or transient ischemic attack. The guideline is addressed to all clinicians who manage secondary prevention for these patients. Evidence-based recommendations are provided for control of risk factors, intervention for vascular obstruction, antithrombotic therapy for cardioembolism, and antiplatelet therapy for noncardioembolic stroke. Recommendations are also provided for the prevention of recurrent stroke in a variety of specific circumstances, includi...
Source: Stroke - June 23, 2014 Category: Neurology Authors: Kernan, W. N., Ovbiagele, B., Black, H. R., Bravata, D. M., Chimowitz, M. I., Ezekowitz, M. D., Fang, M. C., Fisher, M., Furie, K. L., Heck, D. V., Johnston, S. C., Kasner, S. E., Kittner, S. J., Mitchell, P. H., Rich, M. W., Richardson, D., Schwamm, L. H Tags: AHA Statements and Guidelines AHA/ASA Guideline Source Type: research

Guidelines for the Primary Prevention of Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association AHA/ASA Guideline
The aim of this updated statement is to provide comprehensive and timely evidence-based recommendations on the prevention of stroke among individuals who have not previously experienced a stroke or transient ischemic attack. Evidence-based recommendations are included for the control of risk factors, interventional approaches to atherosclerotic disease of the cervicocephalic circulation, and antithrombotic treatments for preventing thrombotic and thromboembolic stroke. Further recommendations are provided for genetic and pharmacogenetic testing and for the prevention of stroke in a variety of other specific circumstances, ...
Source: Stroke - November 24, 2014 Category: Neurology Authors: Meschia, J. F., Bushnell, C., Boden-Albala, B., Braun, L. T., Bravata, D. M., Chaturvedi, S., Creager, M. A., Eckel, R. H., Elkind, M. S. V., Fornage, M., Goldstein, L. B., Greenberg, S. M., Horvath, S. E., Iadecola, C., Jauch, E. C., Moore, W. S., Wilson Tags: AHA Statements and Guidelines AHA/ASA Guideline Source Type: research

Classical Risk Factors for Ischemic Stroke are not Associated with Inpatient Post-Stroke Mortality in Sickle Cell Disease
Sickle cell disease is a common haemoglobinopathy that significantly increases the risk of ischemic stroke. Because the risk factors for ischemic stroke onset and mortality in non-sickle cell disease patients have been largely elucidated, this paper aims to analyze risk factors for ischemic stroke mortality in sickle cell disease patients, which remain largely unknown.
Source: Journal of Stroke and Cerebrovascular Diseases - September 20, 2021 Category: Neurology Authors: Raphael Miller, Daniel M. Klyde, Santiago R. Unda, Rose Fluss, David J. Altschul Source Type: research

First Ischemic Stroke in Sickle-Cell Disease: Are There Any Adult Specificities? Brief Reports
Conclusions— First-ever IS occurring in adults with SCD has specificities that justify further studies conducted in adults with SCD to improve understanding and management.
Source: Stroke - July 27, 2015 Category: Neurology Authors: Calvet, D., Bernaudin, F., Gueguen, A., Hosseini, H., Habibi, A., Galacteros, F., Bartolucci, P. Tags: Acute Cerebral Infarction Brief Reports Source Type: research

Thrombectomy and thrombolysis in pediatric acute ischemic stroke (S8.007)
Conclusions:In the pediatric AIS population, tPA was associated with increased mortality. Treatment with tPA+/–IAT was associated with decreased discharge home, increased cost, and higher prevalence of ICH. Prevalence of ICH not explained by Moyamoya or sickle cell as those patients were less likely to receive treatment. Limitations include small numbers of treated patients, lack of data on stroke severity or functional outcome, data from years prior to newer thrombectomy devices. Studies of AIS treatment in adults cannot necessarily be extrapolated given the difference in etiologies of pediatric AIS.Disclosure: Dr. ...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Ess, K., Dafer, R., Conners, J., Cherian, L., Ouyang, B., Song, S. Tags: Cerebrovascular Disease and Interventional Neurology: Acute Stroke Treatment Source Type: research

Sickle Mice Are Sensitive to Hypoxia/Ischemia-Induced Stroke but Respond to Tissue-Type Plasminogen Activator Treatment Basic Sciences
Conclusions—Sickle mice are sensitive to hypoxia/ischemia-induced cerebral infarct but benefit from thrombolytic treatment. An increased resistive index in carotid arteries may be an early marker of sickle cell vasculopathy.
Source: Stroke - November 27, 2017 Category: Neurology Authors: Yu-Yo Sun, Jolly Lee, Henry Huang, Mary B. Wagner, Clinton H. Joiner, David R. Archer, Chia-Yi Kuan Tags: Animal Models of Human Disease, Basic Science Research Original Contributions Source Type: research

Toward a Stroke-Free Childhood in Sickle Cell Disease: The 2013 Sherman Lecture Special Report
Source: Stroke - September 23, 2013 Category: Neurology Authors: Adams, R. J. Tags: Other diagnostic testing, Stroke in Children and the Young, Other Stroke Treatment - Medical Special Report Source Type: research

Sickle Cell Disease and Stroke Illustrative Teaching Case
Source: Stroke - May 27, 2014 Category: Neurology Authors: Talahma, M., Strbian, D., Sundararajan, S. Tags: Acute Cerebral Hemorrhage, Acute Cerebral Infarction, Emergency treatment of Stroke, Genetics of Stroke Illustrative Teaching Case Source Type: research

The Genetic Landscape of Cerebral Steno-Occlusive Arteriopathy and Stroke in Sickle Cell Anemia
Sickle cell disease (SCD) is one of the most common autosomal recessive diseases in humans, occurring at a frequency of 1 in 365 African-American and 1 in 50 sub-Saharan African births. Despite progress in managing complications of SCD, these remain a major health burden worldwide. Stroke is a common and serious complication of SCD, most often associated with steno-occlusive cerebral arteriopathy, but little is known about its pathogenesis. Transcranial Doppler ultrasonography is currently the only predictive test for future development of stroke in patients with sickle cell anemia and is used to guide preventative treatment.
Source: Journal of Stroke and Cerebrovascular Diseases - August 1, 2018 Category: Neurology Authors: Catherine Amlie-Lefond, Jonathan Flanagan, Julie Kanter, William B. Dobyns Tags: Review Article Source Type: research

Repurposing the KCa3.1 Blocker Senicapoc for Ischemic Stroke
AbstractSenicapoc, a small molecule inhibitor of the calcium-activated potassium channel KCa3.1, was safe and well-tolerated in clinical trials for sickle cell anemia. We previously reported proof-of-concept data suggesting that both pharmacological inhibition and genetic deletion of KCa3.1 reduces infarction and improves neurologic recovery in rodents by attenuating neuroinflammation. Here we evaluated the potential of repurposing senicapoc for ischemic stroke. In cultured microglia, senicapoc inhibited KCa3.1 currents with an IC50 of 7  nM, reduced Ca2+ signaling induced by the purinergic agonist ATP, suppressed express...
Source: Translational Stroke Research - April 24, 2023 Category: Neurology Source Type: research

White Matter Damage Relates to Oxygen Saturation in Children With Sickle Cell Anemia Without Silent Cerebral Infarcts Clinical Sciences
Conclusions— These data show widespread white matter abnormalities in a sample of asymptomatic children with sickle cell anemia, and provides for the first time direct evidence of a relationship between brain microstructure and markers of disease severity (eg, peripheral oxygen saturation and steady-state hemoglobin). This study suggests that diffusion tensor imaging metrics may serve as a biomarker for future trials of reducing hypoxic exposure.
Source: Stroke - June 22, 2015 Category: Neurology Authors: Kawadler, J. M., Kirkham, F. J., Clayden, J. D., Hollocks, M. J., Seymour, E. L., Edey, R., Telfer, P., Robins, A., Wilkey, O., Barker, S., Cox, T. C. S., Clark, C. A. Tags: Stroke in Children and the Young Clinical Sciences Source Type: research